From the labor-intensive "Made in China" to knowledge-based "Created in China," China has embarked on an innovative journey to transform itself. However, to realize the transformation, there is a prerequisite, that is the Intellectual Property Right (IPR) protection. The tracker of emerging technologies says China is poised to surpass Japan as the second-largest spender on biomedical R&D, behind the U.S., as it sets far-ranging targets for new drug development as part of its 12th Five-Year Plan.